The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DTIL | -18.95% | -96.69% | -49.4% | -99% |
| S&P | +16.23% | +94.45% | +14.22% | +139% |
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.02M | -100.0% |
| Gross Profit | -$0.68M | -101.4% |
| Gross Margin | -3766.67% | -3863.9% |
| Market Cap | $46.57M | 17.8% |
| Market Cap / Employee | $0.46M | 0.0% |
| Employees | 102 | 0.0% |
| Net Income | -$23.52M | -171.8% |
| EBITDA | -$21.18M | -183.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $62.24M | -49.6% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $28.03M | 295.3% |
| Short Term Debt | $1.41M | -94.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -56.97% | -66.1% |
| Return On Invested Capital | -95.07% | 15.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.27M | -36.1% |
| Operating Free Cash Flow | -$20.27M | -36.3% |
| Metric | Q3 2024 | Q4 2024 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 175.34 | 2.01 | - | ||
| Price to Book | 0.85 | 0.44 | 0.69 | 0.90 | -50.35% |
| Price to Sales | 0.87 | 0.44 | 0.87 | 36.79 | 4626.35% |
| Price to Tangible Book Value | 0.86 | 0.44 | 0.70 | 0.91 | -50.25% |
| Enterprise Value to EBITDA | 0.28 | 1.07 | 0.15 | -0.64 | -33.22% |
| Return on Equity | 24.4% | 19.0% | -50.8% | -143.9% | -595.45% |
| Total Debt | $30.31M | $30.05M | $29.75M | $29.45M | -4.42% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
